Checks for irregular heartbeat in people with abnormal heart ultrasound results
Tests whether heart ultrasound findings can guide screening for atrial fibrillation in adults.
Plain-language title generated from the registry record
Registry title: AF Screening in Patients With Abnormal Echocardiographic Parameters
Key facts
- Where
- Taipei, TaiwanSee the site
Where in Taiwan
- Taipei Veterans General HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tze-Fan Chao
- Trial code
- NCT07278089
- Record updated
- 11 December 2025
- Original description
To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.Read full original descriptionShow less
Screening of Atrial Fibrillation/Arrhythmia Events in Patients With Abnormal Echocardiographic Parameters: The Randomized, Prospective SAFE-ECHO Study Design and Rationale
To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.
Inclusion: LAE: defined as LAD ≥ 45 mm or LAVI > 34 ml/m2; LVH: defined as LV septal or posterior wall thickness ≥ 15 mm; E/e' > 14; grade II or III diastolic dysfunction; VHD; HF: defined as LVEF < 40% or LVEF ≥40% with clinical presentation compatible with Framingham criteria, New York Heart Association functional classification II-IV, and N-terminal pro-B type natriuretic peptide (NT-proBNP) > 125 pg/ml.
Exclusion: Patients with a history of AF or atrial flutter, congenital heart disease, acute coronary syndrome undergoing urgent percutaneous coronary intervention within 3 months, uncontrolled hyperthyroidism, end-stage renal disease, unstable hemodynamic status or any known major comorbidities or medical conditions with expected life expectancy less than 1 year are excluded.